Brokerages Set Invivyd, Inc. (NASDAQ:IVVD) PT at $8.00

Shares of Invivyd, Inc. (NASDAQ:IVVD) have received a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.00.

Several analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Finally, HC Wainwright upped their price objective on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, October 31st.

Insider Activity at Invivyd

In related news, Director Kevin F. Mclaughlin purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the purchase, the director directly owned 50,000 shares of the company’s stock, valued at $125,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 25.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Invivyd

A number of large investors have recently made changes to their positions in IVVD. RA Capital Management L.P. acquired a new position in Invivyd in the 3rd quarter valued at about $18,831,000. ADAR1 Capital Management LLC acquired a new stake in shares of Invivyd during the 3rd quarter worth about $8,108,000. Vanguard Group Inc. grew its holdings in shares of Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after buying an additional 1,834,970 shares in the last quarter. 683 Capital Management LLC raised its position in shares of Invivyd by 2.3% in the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company’s stock valued at $2,195,000 after buying an additional 70,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Invivyd by 4,964.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,173,747 shares of the company’s stock valued at $5,369,000 after buying an additional 2,130,825 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Trading Down 1.2%

Shares of NASDAQ IVVD opened at $1.61 on Monday. The stock has a market cap of $375.32 million, a P/E ratio of -3.43 and a beta of 0.60. Invivyd has a twelve month low of $0.46 and a twelve month high of $3.07. The stock has a 50 day moving average of $2.27 and a two-hundred day moving average of $1.72.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.